Skip to website navigation Skip to article navigation Skip to content

A page refresh occures when a subject is selected.

Skip article navigation.

3. Notes

35. Trade and other liabilities

35. Trade and other liabilities

€ million

2020

2019

Other payables

91

32

Total non-current trade and other liabilities

91

32

€ million

2020

2019

Trade payables

513

403

Invoices to receive

86

100

Taxes payable, other than income tax

23

43

Payroll and social security liabilities

229

198

Other payables

69

66

Deferred income linked to development agreements

98

3

Other deferred income

24

35

Royalties payables

80

105

Rebates/discounts and other sales allowances payable

717

673

Accrued interest

28

32

Other accrued expenses

271

198

Total current trade and other liabilities

2 138

1 856

The increase of € 60 million in non-current trade and other liabilities comes from acquisition of Engage Therapeutics Inc. (refer to Note 8 ).

The vast majority of the trade and other liabilities are classified as current and consequently the carrying amounts of the total trade and other liabilities is assumed to be a reasonable approximation of fair value.

“Rebates/discounts and other sales allowances payable” include rebates, chargebacks, discounts and accruals for product returns relating to products sold in the U.S. to various customers that are part of commercial and governmental contractual arrangements or other reimbursement programs, including the U.S. Medicaid Drug Rebate program, the U.S. Federal Medicare program and others. The sales returns and allowances are recorded in the same period as the underlying sales as a deduction to sales.

Per management assessment, the total accruals for these items are adequate, based upon currently available information and interpretation of relevant regulations.

As these deductions are based on management estimates, the actual deductions might differ from these estimates. Such differences could impact the accruals recognized in the statement of financial position in future periods and consequently the level of sales recognized in the income statement in future periods, as there is often a time lag of several months between the recording of the estimate and the final accounting of the sales deductions.

The accruals are reviewed and adjusted regularly in light of contractual and legal obligations, historical trends, past experience and projected market conditions.

All returns, chargebacks, rebates and   discounts   that   are not mentioned on the invoice are estimated, deducted from sales and presented on the statement of financial position in the appropriate accrual account. The estimate for future product returns is based on several factors, including: historical return rates, expiration date by product, return rate by closed batches, actual returns processed among others, as well as any other specifically-identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and discontinuances, or a changing competitive environment. Adjustments to these accruals may be required in the future based on revised estimates to our assumptions, which would have an impact on our consolidated results of operations. The U.S. sales return and allowance liability that is included as part of the rebates and discounts payable liability balance amounts to € 554 million as per December 31, 2020 (December 31, 2019: € 549 million).